NCT06868849View on ClinicalTrials.gov

A Study of JMT203 in Patients With Cancer Cachexia

PHASE1RecruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2028

Conditions
Colorectal CancerNon Small Cell Lung CancerPancreatic CancerCancer Cachexia
Interventions
DRUG

JMT203 Injection

"Drug：JMT203 Injection~* Anti-GFRAL monoclonal antibody~* Will be injected subcutaneously once per cycle (3 weeks, on Day 1) for 12 weeks, or will be injected subcutaneously once per cycle (3 weeks, on Day 1)."

Trial Locations (1)

Unknown

RECRUITING

Sir run run shaw Hospital, Zhejiang

All Listed Sponsors
lead

Shanghai JMT-Bio Inc.

INDUSTRY